Dipti Pawaskar

622 total citations
17 papers, 189 citations indexed

About

Dipti Pawaskar is a scholar working on Genetics, Pathology and Forensic Medicine and Rheumatology. According to data from OpenAlex, Dipti Pawaskar has authored 17 papers receiving a total of 189 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 6 papers in Rheumatology. Recurrent topics in Dipti Pawaskar's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers), Urticaria and Related Conditions (6 papers) and Autoimmune Bullous Skin Diseases (5 papers). Dipti Pawaskar is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers), Urticaria and Related Conditions (6 papers) and Autoimmune Bullous Skin Diseases (5 papers). Dipti Pawaskar collaborates with scholars based in United States, Switzerland and Germany. Dipti Pawaskar's co-authors include William J. Jusko, Gerald J. Fetterly, Robert M. Straubinger, Sukyung Woo, Elizabeth A. Repasky, Anthony Roberts, Henrike Feuersenger, Wen Wang, Wen Wang and Allen P. Kaplan and has published in prestigious journals such as Journal of the American College of Cardiology, Journal of Allergy and Clinical Immunology and Pharmaceutical Research.

In The Last Decade

Dipti Pawaskar

17 papers receiving 187 citations

Peers

Dipti Pawaskar

GENET

IMMUN

ONCOL

RHEUM

Pierre–Olivier Schischmanoff France

Eugenio Lucia Italy

Yehua Jin China

Akira Anan Japan

Liye Zhong China

Yuhta Oyama Japan

Helga Droogendijk Netherlands

Vassilios Aslanis United States

G Mathé France

Miguel Franquiz United States

Pierre–Olivier Schischmanoff France

Dipti Pawaskar

44 ×0.5

GENET

55 ×0.8

30 ×0.7

IMMUN

45 ×1.2

ONCOL

11 ×0.4

RHEUM

Citations per year, relative to Dipti Pawaskar Dipti Pawaskar (= 1×) peers Pierre–Olivier Schischmanoff

Countries citing papers authored by Dipti Pawaskar

Since Specialization

Citations

This map shows the geographic impact of Dipti Pawaskar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dipti Pawaskar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dipti Pawaskar more than expected).

Fields of papers citing papers by Dipti Pawaskar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dipti Pawaskar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dipti Pawaskar. The network helps show where Dipti Pawaskar may publish in the future.

Co-authorship network of co-authors of Dipti Pawaskar

This figure shows the co-authorship network connecting the top 25 collaborators of Dipti Pawaskar. A scholar is included among the top collaborators of Dipti Pawaskar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dipti Pawaskar. Dipti Pawaskar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Lawo, John‐Philip, et al.. (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous and Intravenous Garadacimab Following Single‐Dose Administration in Healthy Japanese and White Adults. The Journal of Clinical Pharmacology. 65(4). 466–477. 1 indexed citations

Kithcart, Aaron, Kishor Devalaraja‐Narashimha, Laura Liu, et al.. (2024). EFFECTS OF REGN5381, A NATRIURETIC PEPTIDE RECEPTOR 1 AGONIST ANTIBODY, IN HYPERTENSIVE MOUSE MODELS AND MILDLY HYPERTENSIVE BUT OTHERWISE HEALTHY ADULTS IN A PHASE 1 FIRST-IN-HUMAN STUDY. Journal of the American College of Cardiology. 83(13). 1706–1706. 1 indexed citations

Pawaskar, Dipti, Xi Chen, Frauke May, et al.. (2021). Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312). Clinical and Translational Science. 15(3). 709–720. 16 indexed citations

Roberts, Anthony, et al.. (2021). A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab. Clinical and Translational Science. 15(3). 626–637. 26 indexed citations

Kaplan, Allen P., et al.. (2019). C1 Inhibitor Activity and Angioedema Attacks in Patients with Hereditary Angioedema. The Journal of Allergy and Clinical Immunology In Practice. 8(3). 892–900. 13 indexed citations

Pawaskar, Dipti, Michael A. Tortorici, Bruce L. Zuraw, et al.. (2018). Population pharmacokinetics of subcutaneous C1‐inhibitor for prevention of attacks in patients with hereditary angioedema. Clinical & Experimental Allergy. 48(10). 1325–1332. 8 indexed citations

Zhang, Ying, Michael A. Tortorici, Dipti Pawaskar, et al.. (2018). Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. CPT Pharmacometrics & Systems Pharmacology. 7(3). 158–165. 12 indexed citations

Christiansen, Sandra C., et al.. (2018). Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial. Allergy and Asthma Proceedings. 39(5). 365–370. 11 indexed citations

Pawaskar, Dipti, Iris Jacobs, Ingo Pragst, & Henrike Feuersenger. (2018). Pharmacokinetic Profile of Subcutaneous C1-Esterase Inhibitor (C1-INH [SC]) in Adolescent and Adult Patients with Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 141(2). AB56–AB56. 1 indexed citations

10.

Zuraw, Bruce L., Ian N. Jacobs, Ingo Pragst, et al.. (2018). EXPLORATORY ANALYSIS REVEALS POSITIVE CORRELATION BETWEEN C1 ESTERASE INHIBITOR AND SERUM COMPLEMENT 4 ANTIGEN LEVELS. Annals of Allergy Asthma & Immunology. 121(5). S34–S34. 1 indexed citations

11.

Cicardi, Marco, John Anderson, Jonathan A. Bernstein, et al.. (2017). Risk for Attacks in Hereditary Angioedema (HAE) Population Correlates with C1-inhibitor Functional Activity (C1-INHact). Journal of Allergy and Clinical Immunology. 139(2). AB233–AB233. 1 indexed citations

12.

Bernstein, Jonathan A., Timothy Craig, Hilary Longhurst, et al.. (2017). Placebo-Controlled Trials of C1-Inhibitor (C1-INH) Replacement Therapy for Routine Prevention of Attacks in Patients with Hereditary Angioedema (HAE). Journal of Allergy and Clinical Immunology. 139(2). AB234–AB234. 1 indexed citations

13.

Pawaskar, Dipti, Robert M. Straubinger, Gerald J. Fetterly, et al.. (2013). Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice. Cancer Chemotherapy and Pharmacology. 71(5). 1231–1240. 24 indexed citations

14.

Pawaskar, Dipti, Robert M. Straubinger, Gerald J. Fetterly, et al.. (2013). Physiologically based pharmacokinetic models for everolimus and sorafenib in mice. Cancer Chemotherapy and Pharmacology. 71(5). 1219–1229. 32 indexed citations

15.

Pawaskar, Dipti, Robert M. Straubinger, Gerald J. Fetterly, Weiping Wen, & William J. Jusko. (2012). Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. The AAPS Journal. 15(1). 78–84. 15 indexed citations

16.

Pawaskar, Dipti, Robert M. Straubinger, Gerald J. Fetterly, Wen Wang, & William J. Jusko. (2012). Interactions of Everolimus and Sorafenib in Whole Blood Lymphocyte Proliferation. Pharmaceutical Research. 30(3). 707–713. 2 indexed citations

17.

Woo, Sukyung, Dipti Pawaskar, & William J. Jusko. (2009). Methods of utilizing baseline values for indirect response models. Journal of Pharmacokinetics and Pharmacodynamics. 36(5). 381–405. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact